Research Embargoes and the Ingelfinger Rule

Two rules are often blurred when medical research reaches the news. A media embargo asks reporters and others with advance access to wait until a stated time. A prior-publication policy asks whether earlier public sharing makes a manuscript ineligible for a journal. One coordinates timing. The other protects a journal's standard for originality and its chosen publication process.

The “Ingelfinger rule” is the historical name most closely associated with the second question. Its modern descendants are not one universal rule. Current policies vary by journal, article type, preprint server, scientific meeting, public-health need, and the detail released.

The historical rule and its purpose#

In 1969, NEJM editor Franz Ingelfinger formulated a policy after a news outlet summarized research scheduled for the journal. A later NEJM editorial described the policy as discouraging detailed dissemination in medical newspapers and general media before journal publication.

The policy served more than one interest. The journal wanted original material and protected the news value of publication. It also argued that clinicians and the public should have access to the full, peer-reviewed report when headlines appeared, so claims could be examined rather than accepted from a summary.

That history explains why “Ingelfinger rule” can refer to two related ideas: no prior publication and limits on prepublication publicity. Treating the phrase as a timeless ban misses how journal policies have changed, especially with preprint servers, online-first publication, meeting websites, and public-health communication.

What a media embargo does#

Journals may give qualified journalists advance access to an accepted article, press materials, and author contacts. In exchange, the journalists agree not to publish until the embargo lifts. The interval can support reporting, outside expert interviews, and reading of the full article.

ICMJE describes the arrangement as an honor system. It can reduce pressure to race competitors with incomplete reporting, but it also serves journal interests and can concentrate attention at one scheduled moment. A reporter's access under embargo does not imply endorsement, exclusivity, or permission to ignore weaknesses in the study.

An embargo is not peer review. The material under embargo may already be accepted by a journal, but a conference, agency, funder, or company can also embargo a report or announcement. Readers still need to ask what document exists, whether it was peer reviewed, which version was supplied, and whether the news claim matches the reported results.

Prior publication is a different test#

A journal deciding whether to consider a manuscript asks whether substantially the same work has already been published or released in a form that conflicts with its policy. Duplicate publication can distort the evidence record, waste editorial review, split related results, and make one study look like several.

The difficult cases are not exact duplicate journal articles. They are conference abstracts, detailed press releases, investor presentations, institutional reports, dissertations, trial-registry results, government submissions, and preprints. The answer depends on the journal and the amount of scientific detail made public.

ICMJE recommends that authors disclose related reports and provide copies to the editor. It also says that a preprint is not duplicate publication, while asking journals to state whether preprint posting affects their interest. That distinction has helped normalize preprints without forcing every journal to adopt identical policies.

The guide to peer review and preprints explains why a preprint and a version of record should remain visibly connected but should not be treated as interchangeable.

Current policy is more specific than folklore#

NEJM's current editorial policy states that presenting at scientific meetings, posting on a nonprofit preprint server, and releasing results to government agencies for statutory or urgent public-health needs do not violate its no-prior-publication policy. Authors are expected to tell the journal about a related preprint.

The same policy places limits around discussion of a submission and describes a scheduled media embargo for accepted articles. Those details can change. An author should consult the current target-journal policy rather than rely on a colleague's memory of “the Ingelfinger rule.”

Other journals may accept commercial preprint platforms, impose different disclosure requirements, or treat detailed media coverage differently. Some disciplines have longer traditions of working papers than clinical medicine. A rule that applies to one journal or field should not be projected onto another.

Scientific meetings occupy a middle ground#

Meeting abstracts and presentations allow timely scientific exchange. ICMJE says policies limiting prepublication publicity should not block media accounts of scientific presentations or meeting abstracts. Researchers can discuss what they presented, while recognizing that releasing substantially more detail may affect a journal's evaluation.

The boundary becomes harder when a meeting posts the full slide deck, a complete manuscript, extensive supplementary data, or a detailed press package. The relevant question is not whether the item was called an “abstract.” It is how much of the study's scientific substance became publicly available and what the target journal's policy says.

Meeting findings are often preliminary. The sample, analyses, or conclusions can change before journal publication. Reporting should identify the item as a conference presentation, link to the available abstract or materials, and avoid implying that a later article will be identical.

Preprints changed the practical landscape#

A preprint makes a manuscript public before journal peer review. It can establish a timestamp, invite criticism, and speed access. It can also circulate findings that later change or never reach a journal.

ICMJE advises authors to choose preprint archives with clear notices that the work is not peer reviewed, author disclosures, funding information, versioning, commenting, withdrawal practices, and links to later publication. Crossref supports distinct metadata and persistent links between preprints and versions of record.

Those links matter. A news story based on a preprint should continue to identify it as a preprint after a journal article appears and should add the later record. A reader should be able to see what changed. A journal embargo on the version of record does not retroactively make the already public preprint secret.

Public-health exceptions need accountable decisions#

Some findings cannot wait for the ordinary publication calendar. An outbreak, serious new adverse effect, environmental hazard, or urgent result affecting current care may require communication to authorities and clinicians before a journal article appears.

ICMJE says responsible public-health authorities should decide when exceptional early release is needed and that the editor should be consulted if journal consideration is sought. NEJM likewise lists urgent public-health release to government agencies among its exceptions.

This exception should not be confused with promotional urgency. A claim that results are “important” is not enough. Early release should identify who made the decision, what evidence is available, what remains uncertain, and where updates will appear.

How to report embargoed research well#

The embargo clock should never become the story's evidence standard. A careful report asks:

• Is the source a full article, preprint, abstract, press release, or presentation?
• Has the material been peer reviewed, and by whom?
• Does the headline use the same outcome, population, and time frame as the source?
• Are absolute effects, harms, uncertainty, and study limitations available?
• Who funded the work, and what role did the sponsor have?
• Is there an earlier preprint or later version that should be linked?

The deadline may be fixed, but publication is optional. If the full evidence cannot be checked, waiting can be the more accurate decision.

The guide to fact-checking health news offers a reader-facing version of the same source checks.

The useful distinction#

Use precise language. Say “the journal's media embargo lifts at…” when the issue is timing. Say “the journal's prior-publication policy permits…” when the issue is manuscript eligibility. Say “preprint” or “conference abstract” when that is the document being discussed.

The historical name is useful context, not a substitute for the current written policy. Research communication works best when each version is labeled, related records are linked, and urgent exceptions have an accountable public-interest reason.

References#

1. ICMJE recommendations on journals and the media
2. ICMJE recommendations on overlapping and prior publication
3. New England Journal of Medicine editorial policies
4. Relman, The Ingelfinger Rule
5. Crossref guidance for linking preprints and later articles

This article is educational, not legal, publishing, employment, or media-relations advice. Authors and journalists should consult the current policy that governs their specific submission or embargo.